



# CURRICULUM VITAE

## PERSONAL DETAILS

**WORK ADDRESS** Department of Comparative Biomedical Sciences, College of Veterinary Medicine, Mississippi State University, P.O. Box 6100, 240 Wise Center Dr., Starkville, MS 39762, USA

**CONTACT** Tel (Departmental Office): +1-(662)-325-1130  
E-mail: mp2358@msstate.edu

**ORCID ID** 0000-0002-1450-3552

**SCOPUS ID** 6506763972

**WEB OF SCIENCE ID** AAG-6274-2020

**WEB PAGES** <https://www.vetmed.msstate.edu/directory/mp2358>  
<https://www.linkedin.com/in/michail-mihalis-panagiotidis-3b470226>  
<https://orcid.org/0000-0002-1450-3552>  
<https://www.scopus.com/authid/detail.uri?authorId=6506763972>  
[https://scholar.google.com/citations?hl=en&user=l6BfnYAAAAJ&view\\_op=list\\_works&sortby=pubdate](https://scholar.google.com/citations?hl=en&user=l6BfnYAAAAJ&view_op=list_works&sortby=pubdate)

## EDUCATIONAL DETAILS

**1999-2004** DOCTOR OF PHILOSOPHY (PHD) IN TOXICOLOGY  
Department of Pharmaceutical Sciences, University of Colorado, USA

**1994-1996** MASTER OF SCIENCE (MSc) BY RESEARCH  
Department of Molecular & Cell Biology, University of Aberdeen, Scotland, UK

**1993-1994** POSTGRADUATE DIPLOMA (PGDIP) IN HUMAN NUTRITION & METABOLISM  
Department of Human Nutrition, University of Aberdeen, Scotland, UK

**1992-1993** POSTGRADUATE DIPLOMA (PGDIP) IN MEDICAL & MOLECULAR GENETICS  
Department of Molecular & Cell Biology, University of Aberdeen, Scotland, UK

**1988-1992** BACHELOR OF SCIENCE (BSc) IN PURE SCIENCE  
Department of Molecular & Cell Biology, University of Aberdeen, Scotland, UK

## PROFESSIONAL EXPERIENCE

**01/2025-present** PROFESSOR & DEPARTMENT HEAD  
Department of Comparative Biomedical Sciences, Mississippi State University, USA

**03/2020-12/2024** PROFESSOR  
Postgraduate School, Cyprus Institute of Neurology & Genetics, CYPRUS

**11/2019-12/2024** SENIOR SCIENTIST & DEPARTMENT HEAD  
Department of Cancer Genetics, Therapeutics & Ultrastructural Pathology, Cyprus Institute of Neurology & Genetics, CYPRUS

**09/2016-10/2019** PROFESSOR  
Department of Applied Sciences, Northumbria University, England, UK

**01/2013-08/2016** PROFESSOR & CHAIR  
School of Life Sciences, Heriot Watt University, Scotland, UK

**01/2012-12/2012** ASSISTANT PROFESSOR  
Department of Pathological Anatomy, University of Ioannina, GREECE

**07/2009-06/2011** ADJUNCT ASSISTANT PROFESSOR



**07/2007-06/2009** School of Community Health Sciences, University of Nevada-Reno, USA  
ASSISTANT PROFESSOR

**08/2006-06/2007** School of Community Health Sciences, University of Nevada-Reno, USA  
RESEARCH ASSISTANT PROFESSOR

**07/2004-07/2006** Department of Nutrition, University of North Carolina-Chapel Hill, USA  
IRTA POSTDOCTORAL FELLOW

Laboratory of Signal Transduction, NIEHS/NIH, USA

## RESEARCH EXPERIENCE (LAST 5 YEARS)

### PUBLICATIONS IN PEER-REVIEWED JOURNALS

- 1- Mitsiogianni M, Trafalis DT, Franco R, Zoumpourlis V, Pappa A, Panayiotidis MI. Sulforaphane and iberin are potent epigenetic modulators of histone acetylation and methylation modifications in malignant melanoma. *Eur. J. Nutr.*, 60(1): 147-158, 2021
- 2- Tsochantaridis I, Roupas A, Voulgaridou G-P, Giatromanolaki A, Koukourakis MI, Panayiotidis MI, Pappa A. Aldehyde dehydrogenase 1B1 is associated with altered cell morphology, proliferation, migration and chemosensitivity in human colorectal adenocarcinoma cells. *Biomedicines*, 9(1): E44, 2021
- 3- Mitsiogianni M, Kyriakou S, Anestopoulos I, Trafalis DT, Deligiorgi MV, Franco R, Pappa A, Panayiotidis MI. An evaluation of the anti-carcinogenic response of major isothiocyanates in non-metastatic and metastatic melanoma cells. *Antioxidants*, 10(2): E284, 2021
- 4- Kyriakou S, Cheung W, Mantso T, Mitsiogianni M, Anestopoulos I, Veuger S, Trafalis DT, Franco R, Pappa A, Tetard D, Panayiotidis MI. A novel methylated analogue of L-Mimosine exerts therapeutic potency through ROS production and ceramide-induced apoptosis in malignant melanoma. *Invest. New Drugs*, 39(4): 971-986, 2021
- 5- Voulgaridou G-P, Mantso T, Anestopoulos I, Klavaris A, Katzastra C, Kiouisi D-E, Mantela M, Galanis A, Gardikis K, Banat IM, Gutierrez T, Salek K, Euston SR, Panayiotidis MI, Pappa A. Toxicity profiling of biosurfactants produced by novel marine bacterial strains. *Int. J. Mol. Sci.*, 22(5): 2383, 2021
- 6- Mitsiogianni M, Anestopoulos I, Kyriakou S, Trafalis DT, Franco R, Pappa A, Panayiotidis MI. Benzyl and phenethyl isothiocyanates as promising epigenetic drug compounds by modulating histone acetylation and methylation marks in malignant melanoma. *Invest. New Drugs*, 39(6): 1460-1468, 2021
- 7- Baliou S, Adamaki M, Ioannou P, Pappa A, Panayiotidis MI, Christodoulou I, Spandidos DA, Kyriakopoulos AM, Zoumpourlis V. Ameliorative effect of taurine against diabetes and renal-associated disorders. *Med. Int.*, 1: 3, 2021
- 8- Sagredou S, Dalezis P, Papadopoulou E, Voura M, Deligiorgi MV, Nikolaou M, Panayiotidis MI, Nasioulas G, Sarli V, Trafalis DT. Effects of a novel thiaziazole derivative with high anticancer activity on cancer cell immunogenic markers: mismatch repair system, PD-L1 expression, and tumor mutation burden. *Pharmaceutics*, 13(6): 885, 2021
- 9- Richter J, Fanis P, Tryfonos C, Koptides D, Krashias G, Bashiardes S, Hadjisavvas A, Loizidou M, Oulas A, Alexandrou D, Kalakouta A, Panayiotidis MI, Spyrou GM, Christodoulou C. Molecular Epidemiology of SARS-CoV-2 in Cyprus. *PLOS One*, 16(7): e0248792, 2021
- 10- Baliou S, Adamaki M, Ioannou P, Pappa A, Panayiotidis MI, Spandidos DA, Christodoulou I, Kyriakopoulos AM, Zoumpourlis V. Protective role of taurine against oxidative stress. *Mol. Med. Rep.*, 24(2): 605, 2021
- 11- Giatromanolaki A, Anestopoulos I, Panayiotidis MI, Mitrakas A, Pappa A, Koukourakis MI. Prognostic relevance of CD4/CD8/CD20 composition of tumor infiltrating lymphocytes in operable non-small cell lung cancer patients. *Anticancer Res.*, 41(8): 3989-3995, 2021
- 12- Theofilou SP, Antoniou C, Potamiti L, Hadjisavvas A, Panayiotidis M, Savva PG, Fotopoulos V, Costa CN. Immobilized Ag-nanoparticles for environmental applications: Elucidation of immobilized silver-induced inhibition mechanism of Escherichia coli. *J. Environ. Chem. Eng.*, 9: 106001, 2021

- 13-** Yiangou K, Kyriacou K, Kakouri E, Marcou Y, Panayiotidis MI, Loizidou MA, Hadjisavvas A, Michailidou K. Combination of a 15-SNP polygenic risk score and classical risk factors for the prediction of breast cancer risk in Cypriot women. *Cancers*, 13(18): 4568, 2021
- 14-** Stavropoulos F, Sargiannidou I, Potamiti L, Kagiava A, Panayiotidis MI, Lee YJ, Kleopa KA. Aberrant mitochondrial dynamics and exacerbated response to neuroinflammation in a novel mouse model of CMT2A. *Int. J. Mol. Sci.*, 22(21): 11569, 2021
- 15-** Tsochantaridis I, Voulgaridou G-P, Giatromanolaki A, Koukourakis MI, Panayiotidis MI, Pappa A. Profiling of aldehyde dehydrogenase isoforms in *in vitro* formed tumorspheres. *Anticancer Res.*, 41(11): 5481-5488, 2021
- 16-** Kyriakou S, Tragkola V, Plioukas M, Anestopoulos I, Chatzopoulou PS, Sarrou E, Trafalis DT, Deligiorgi MV, Franco R, Pappa A, Panayiotidis MI. Chemico-biological assessment of anticancer potency of *Salvia Fruticosa* extracts in an *in vitro* model of human malignant melanoma. *Plants*, 10(11): 2472, 2021
- 17-** Krashias G, Deeba E, Costantinou A, Hadjiagapiou M, Koptides D, Richter J, Tryfonos C, Bashiardes S, Lambrianides N, Loizidou MA, Hadjisavvas A, Panayiotidis MI, Christodoulou C. Characterisation of IgG antibody response against Sars-CoV 2 (Covid-19) in the Cypriot population. *Microorganisms*, 10(1): 85, 2021
- 18-** Kalogirou M, Ioanou S, Kolovos P, Prokopiou E, Potamiti L, Kyriacou K, Panagiotidis M, Ioannou M, Fella E, Panayiotou Worth E, Georgiou T. Omega-3 fatty acids promote neuroprotection, decreased apoptosis and reduced glial cell activation in the retina of a mouse model of OPA1-related autosomal dominant optic atrophy. *Exp. Eye Res.*, 215: 108901, 2022
- 19-** Kyriakou S, Tragkola V, Heba A, Anestopoulos I, Amery T, Stewart K, Winyard P, Trafalis DT, Franco R, Pappa A, Panayiotidis MI. Evaluation of bioactive properties of lipophilic fractions of edible and non-edible parts of *Nasturtium officinale* (watercress) in a model of human malignant melanoma cells. *Pharmaceuticals*, 15: 141, 2022
- 20-** Bauer AS, Leppik K, Galić K, Anestopoulos I, Panayiotidis MI, Agriopoulou A, Milousi M, Uysal-Unalan I, Varzakas T, Krauter V. Cereal and Confectionary Packaging: Background, Application and Shelf-Life Extension. *Foods*, 11(5): 697, 2022
- 21-** Lukose CC, Anestopoulos I, Mantso T, Bowen L, Panayiotidis MI, Birkett M. Thermal activation of Ti(1-x)Au(x) thin films with enhanced hardness and biocompatibility. *Bioact. Mater.*, 15: 426-445, 2022
- 22-** Kyriakou S, Trafalis DT, Deligiorgi MV, Franco R, Pappa A, Panayiotidis MI. Assessment of methodological pipelines for the determination of isothiocyanates derived from natural sources. *Antioxidants*, 11(4): 642, 2022
- 23-** Petrakis G, Mantso T, Koukourakis MI, Panayiotidis MI, Botaitis S. Effectiveness of hyperthermia as a monotherapy and adjuvant therapy approaches against an *in vitro* model of colorectal carcinoma. *Anticancer Res*, 42(5): 2363-2374, 2022
- 24-** Giatromanolaki A, Mitrakas A, Anestopoulos I, Kontosis A, Koukourakis IM, Pappa A, Panayiotidis MI, Koukourakis MI. Expression of CD47 and SIRPα macrophage immune-checkpoint pathway in non-small-cell lung cancer. *Cancers*, 14(7): 1801, 2022
- 25-** Yilmaz V, Louka P, Potamiti L, Panayiotidis MI, Strati K. A novel lineage-tracking mouse model for studying early MmuPV1 infections. *eLife*, 11: e72638, 2022
- 26-** Kyriakoudi S, Theodoulou A, Potamiti L, Schumacher F, Zachariou M, Papacharalambous R, Kleuser B, Panayiotidis MI, Drousiotou A, Petrou PP. Stbd1 deficient mice display insulin resistance associated with enhanced hepatic ER-mitochondria contact. *Biochimie*, 200: 172-183, 2022
- 27-** Abdelaal G, Carter A, Panayiotides MI, Tetard D, Veuger S. Novel iron chelator SK4 demonstrates cytotoxicity in a range of tumour derived cell lines. *Front. Mol. Biosci.*, 9: 1005092, 2022
- 28-** Zompra AA, Chasapi SA, Twigg MS, Salek K, Anestopoulos I, Galanis A, Pappa A, Gutierrez T, Banat IM, Marchant R, Euston SR, Panayiotidis MI, Spyroulias GA. Multi-method biophysical analysis in discovery, identification, and in-depth characterization of surface-active compounds. *Front. Mar. Sci.*, 9: 1023287, 2022

- 29-** Lukose CC, Chavignon C, Mantso T, Panayiotidis MI, Birkett M. Enhanced mechanical and biocompatibility performance of Ti(1-x)Ag(x) coatings through intermetallic phase modification. *Mater. Charact.*, 194: 112401, 2022
- 30-** Anestopoulos I, Kyriakou S, Tragkola V, Paraskevaidis I, Tzima E, Mitsiogianni M, Deligiorgi MV, Petrakis G, Trafalis DT, Botaitis S, Giatromanolaki A, Koukourakis MI, Franco R, Pappa A, Panayiotidis MI. Targeting the epigenome in malignant melanoma: facts, challenges and therapeutic promises. *Pharmacol. Ther.*, 240: 108301, 2022
- 31-** Kyriakou S, Michailidou K, Amery T, Stewart K, Winyard P, Trafalis DT, Franco R, Pappa A, Panayiotidis MI. Polyphenolic and glucosinolate profiling of aerial parts of *Nasturtium officinale* (Watercress). *Front. Plant Sci.*, 13: 998755, 2022
- 32-** Spyridopoulou K, Kyriakou S, Nomikou A, Roupas A, Ermogenous A, Karamanoli K, Moyankova D, Djilianov D, Galanis A, Panayiotidis MI, Pappa A. Chemical profiling, antiproliferative and antimigratory capacity of *Haberlea rhodopensis* extracts in an *in vitro* platform of various human cancer cell lines. *Antioxidants*, 11(12): 2305, 2022
- 33-** Kouis P, Kakkoura MG, Elia SA, Ioannou P, Anagnostopoulou P, Potamiti L, Loizidou MA, Panayiotidis MI, Kyriacou K, Hadjisavvas A, Yiallourous P. Observational study of health utilities in adult Primary Ciliary Dyskinesia patients: associations with molecular diagnosis, clinical phenotype and HR-QoL measures. *Multidiscip. Respir. Med.*, 17: 881, 2022
- 34-** Figlioli G, Billaud A, Ahearn TU, Antonenkova AN, Becher H, Beckmann MW, Behrens S, Benitez J, Bermisheva M, Blok MJ, Bogdanova NV, Bonanni, Brauch H, Burwinkel B, Camp NJ, Campbell A, Castelao JE, Cessna MH, Chanock SJ, Chanock S, NBCS Collaborators, Czene K, Devilee P, Dörk T, Engel C, Eriksson M, Fasching PA, Figueroa JD, Gabrielson M, Gago-Dominguez M, García-Closas M, Giles GG, González-Neira A, Grassmann F, Guénel P, Gündert M, Hadjisavvas A, Hahnen E, Hall P, Hamann U, Harrington PA, He W, Hillemanns P, Hollestelle A, Hooning MJ, Hoppe R, Howell A, Humphreys K, kConFab Investigators, Jager A, Jakubowska A, Khusnutdinova EK, Ko Y-D, Kristensen VN, Lindblom A, Lissowska J, Lubiński J, Mannermaa A, Margolin S, Mavroudis D, Newman WG, Obi N, Panayiotidis MI, Rashid MU, Rhenius V, Rookus MA, Saloustros E, Sawyer EJ, Schmutzler RK, Shah M, Sironen R, Suvanto M, Tollenaar Rob A.E.M, Tomlinson I, Truong T, van der Kolk LE, van Veen EM, Wappenschmidt B, Yang XR, Bolla MK, Dennis J, Dunning AM, Easton DF, Lush M, Michailidou K, Pharoah PDP, Wang Q, The BCAC Consortium, Adank MA, Schmidt MK, Andrulis IL, Chang-Claude J, Nevanlinna H, Chenevix-Trench G, Evans DG, Milne RL, Radice P, Peterlongo P. *FANCM* missense variants and breast cancer risk: a case-control association study on 75,156 European women. *Eur. J. Hum. Genet.*, 31(5): 578-587, 2023
- 35-** Abdul Wasy Zia, Anestopoulos I, Panayiotidis MI, Birkett M. Soft Diamond-like Carbon Coatings with Superior Biocompatibility for Medical Applications. *Ceram. Int.*, 49(11): 17203-17211, 2023
- 36-** Voulgaridou GP, Theologidis V, Venetikidou M, Tsohandaridis I, Tsolou A, Koffa M, Panayiotidis MI, Pappa A. Investigating the functional roles of aldehyde dehydrogenase 3A1 in human corneal epithelial cells. *Int. J. Mol. Sci.*, 24(6): 5845, 2023
- 37-** Kyriakou S, Tragkola V, Paraskevaidis I, Plioukas M, Trafalis DT, Franco R, Pappa A, Panayiotidis MI. Chemical characterization and biological evaluation of *Epilobium parviflorum* extracts in an *in vitro* model of human malignant melanoma. *Plants*, 12(8): 1590, 2023
- 38-** Ververis A, Ioannou K, Kyriakou S, Violaki N, Panayiotidis MI, Chatzopoulou PS, Plioukas M, Christodoulou K. *Sideritis scardica* extracts demonstrate neuroprotective activity against Aβ<sub>25-35</sub> toxicity. *Plants*, 12(8): 1716, 2023
- 39-** Abdul Wasy Zia, Anestopoulos I, Panayiotidis MI, Bowen L, Birkett M. Biomechanical characteristics of silver enriched diamond-like carbon coatings for medical applications. *J. Alloys Compd.*, 958: 170473, 2023
- 40-** Figlioli G, Billaud A, Wang Q, Bolla MK, Dennis J, Lush M, Kvist A, Adank MA, Aheren TU, Antonenkova NN, Auvinen PK, Behrens S, Bermisheva M, Bogdanova NV, Bojesen SE, Bonanni B, Brüning T, Camp NJ, Campbell A, Castelao JE, Cessna MH, NBCS Collaborators, Czene K, Devilee P, Dörk T, Eriksson M, Fasching PA, Lavlund Flyger H, Gabrielson M, Gago-Dominguez M, García-Closas

M, Glendon G, Gómez García EB, Gonzalez-Neira A, Grassmann F, Guénel P, Hahnen E, Hamann U, Hillemanns P, Hooning MJ, Hoppe R, Howell A, Humphreys K, KconFab Investigators, Jakubowska A, Khusnutdinova EK, Kristensen VN, Lindblom A, Loizidou MA, Lubiński J, Mannermaa A, Maurer T, Mavroudis D, Newman WG, Obi N, [Panayiotidis MI](#), Radice P, Rashid M, Rhenius V, Ruebner M, Saloustros E, Sawyer E, Schmidt MK, Schmutzler R, Shah M, Southey MC, Tomlinson I, Truong T, Van Veen EM, Wendt C, Yang XR, Michailidou K, Dunning AM, Pharoah PDP, Easton DF, Andrulis IL, Evans DGR, Hollestelle A, Chang-Claude J, Milne RL, Peterlongo P. Spectrum and frequency of germline *FANCM* protein-truncating variants in 44,803 European female breast cancer cases. *Cancers*, 15(13): 3313, 2023

**41-** Lukose CC, Anastopoulos I, Bowen L, [Panayiotidis MI](#), Birkett M. Adatom controlled emergence of high hardness in biocompatible beta-Ti<sub>3</sub>Au intermetallic thin film surfaces. *Surf. Interfaces*, 40: 103034, 2023

**42-** Birkett M, Abdul Wasy Zia, Devarajan DK, Soni, [Panayiotidis MI](#), Joyce TJ, Tambuwala, MM, Serrano-Aroca A. Multi-functional bioactive silver- and copper-doped diamond-like carbon coatings for medical implants. *Acta Biomater.*, 167: 54-68, 2023

**43-** Wilcox N, Dumont M, González-Neira A, Carvalho S, Beuparlant CJ, Crotti M, Luccarini C, Soucy P, Dubois S, Nuñez-Torres R, Pita G, Alonso MR, Álvarez N, Baynes C, Becher H, Behrens S, Bolla MK, Castela JE, Chang-Claude J, Cornelissen S, Dennis J, Dörk T, Engel C, Gago-Dominguez M, Guénel P, Hadjisavvas A, Hahnen E, Hartman M, Herráez B, SGBCC Investigators, Jung A, Keeman R, Kiechle M, Li J, Loizidou MA, Lush M, Michailidou K, [Panayiotidis MI](#), Sim X, Teo SH, Tyrer JP, Lizet E, van der Kolk LE, Wahlström C, Wang Q, Benitez J, Schmidt MK, Schmutzler RK, Pharoah PDP, Droit A, Dunning AM, Kvist A, Devilee P, Easton DF, Simard J. Exome sequencing identifies novel susceptibility genes and defines the contribution of coding variants to breast cancer risk. *Nat. Genet.*, 55(9): 1435-1439, 2023

**44-** Abdelaal G, Carter A, Cheung W, [Panayiotidis MI](#), Racey S, Tetard D, Veuger S. Novel Iron chelator SK4 drives cytotoxicity through inhibiting mitochondrial metabolism in ovarian and triple negative breast cancer cell lines. *Biomedicines*, 11(7): 2073, 2023

**45-** Zanti M, Loizidou MA, O'Mahony DG, Dorling L, Dennis J, Devilee P, Easton DF, [Panayiotidis MI](#), Hadjisavvas A, Michailidou K. Multi-gene panel testing and association analysis in Cypriot breast cancer cases and controls. *Front. Genet.*, 14: 1248492, 2023

**46-** Ververis A, Kyriakou S, Ioannou K, Chatzopoulou PS, [Panayiotidis MI](#), Plioukas M, Christodoulou K. Chemical profiling and antioxidant and anti-amyloid capacities of *Salvia fruticosa* extracts from Greece. *Plants*, 12(18): 3191, 2023

**47-** Kyriakou S, Potamiti L, Demosthenous N, Amery T, Stewart K, Winyard PG, Franco R, Pappa A, [Panayiotidis MI](#). A naturally-derived watercress flowers based phenethyl isothiocyanate-enriched extract induces activation of intrinsic apoptosis via subcellular ultrastructural and Ca<sup>2+</sup> efflux alterations in an *in vitro* model of human malignant melanoma. *Nutrients*, 15(18): 4044, 2023

**48-** Lukose CC, Anastopoulos I, Panagiotidis I-S, Zoppi G, Black AM, Dover LG, Bowen L, Serrano-Aroca A, Liu TX, Mendola L, Morrone D, [Panayiotidis MI](#), Birkett M. Biocompatible Ti<sub>3</sub>Au-Ag/Cu thin film coatings with enhanced mechanical and antimicrobial functionality. *Biomater. Res.*, 27(1): 93, 2023

**49-** Orfanakos K, Aliferis CE, Verigos EK, Deligiorgi MV, Verigos KE, [Panayiotidis MI](#), Nikolaou M, Trafalis DT. Predictive value of 8-hydroxydeoxyguanosine (8-OHdG) serum concentrations in irradiated Non-Small Cell Lung Carcinoma (NSCLC) patients. *Biomedicines*, 12(1): 134, 2024

**50-** Kyriakou S, Demosthenous N, Amery T, Stewart K, Winyard PG, Franco R, Pappa A, [Panayiotidis MI](#). Naturally-derived phenethyl isothiocyanate modulates induction of oxidative stress *via* its *N*-acetylated cysteine conjugated form in malignant melanoma. *Antioxidants*, 13(1): 82, 2024

**51-** Constantinou M, Panteli C, Potamiti L, [Panayiotidis MI](#), Agapiou A, Christodoulou S, Andreou C. Advancing Breath Diagnostics: 3D Mesh SERS Sensor via Dielectrophoretic Alignment of Solution-Processed Au Nanoparticle-Decorated TiO<sub>2</sub> Nanowires. *Adv. Sens. Res.*, 2300161, 2024

**52-** Anastopoulos I, Paraskevaidis I, Kyriakou S, Giova L, Trafalis DT, Botaitis S, Franco R, Pappa A, [Panayiotidis MI](#). Isothiocyanates potentiate Tazemetostat-induced apoptosis by modulating the expression

of apoptotic genes, members of Polycomb Repressive Complex 2 and levels of tri-methylating lysine 27 at Histone 3 in malignant melanoma. *Int. J. Mol. Sci.*, 25(5): 2745, 2024

**53-** Lukose CC, Anestopoulos I, Panayiotidis MI, Birkett M. Nanomechanical and microstructural characterization of biocompatible Ti<sub>3</sub>Au thin films grown on glass and Ti<sub>6</sub>Al<sub>4</sub>V substrates. *ACS Biomater. Sci. Eng.*, 10(5): 2935-2944, 2024

**54-** Vasileiadis A, Bozidis P, Konstantinidis K, Kesesis N, Potamiti L, Kolliopoulou A, Beloukas A, Panayiotidis MI, Havaki S, Gorgoulis VG, Gartzonika K, Karakasiliotis I. A novel *Dhillonvirus* phage against *Escherichia coli* bearing a unique gene of intergeneric origin. *Curr. Issues Mol. Biol.*, 46(9): 9312-9329, 2024

**55-** Abdul Wasy Zia, Anestopoulos I, Bowen L, Panayiotidis MI, Birkett M. Precision depth-controlled isolated silver nanoparticle-doped diamond-like carbon coatings with enhanced ion release, biocompatibility and mechanical performance. *Surf. Coat. Technol.*, 493: 131281, 2024

**56-** Tragkola V, Anestopoulos I, Kyriakou S, Amery T, Franco R, Pappa A, Panayiotidis MI. Naturally-derived phenethyl isothiocyanate modulates apoptotic induction through regulation of the intrinsic cascade and resulting apoptosome formation in human malignant melanoma cells. *Toxicol. Mech. Methods*, 34(9):985-999, 2024

**57-** Davidson AL, Michailidou K, Parsons MT, Fortuno C, Bolla MK, Wang Q, Dennis J, Naven M, Abubakar M, Ahearn TU, Alonso MR, Andrulis IL, Antoniou AC, Auvinen P, Behrens S, Bermisheva MA, Bogdanova NV, Bojesen SE, Brüning T, Byers HJ, Camp NJ, Campbell A, Castelao JE, Cessna MH, Chang-Claude J, Chanock SJ, Chenevix-Trench G, NBCS Collaborators, Collée JM, Czene K, Dörk T, Eriksson M, Evans DG, Fasching PA, Figueroa JD, Flyger H, Gago-Dominguez M, García-Closas M, Glendon G, González-Neira A, Grassmann F, Gronwald J, Guénel P, Hadjisavvas A, Haeberle L, Hall P, Hamann U, Hartman M, Ho PJ, Hooning MJ, Hoppe R, Howell A, kConFab Investigators, Jakubowska A, Khusnutdinova EK, Kristensen VN, Li J, Lim J, Lindblom A, Liu J, Lophatananon A, Mannermaa A, Mavroudis DA, Mensenkamp AR, Milne RL, Muir K, Newman WG, Obi N, Panayiotidis MI, Park SK, Park SK, Park-Simon TW, Peterlongo P, Radice P, Rashid MU, Rhenius V, Saloustros E, Sawyer EJ, Schmidt MK, Seibold P, Shah M, Southey MC, Teo SH, Tomlinson I, Torres D, Truong T, van de Beek I, van der Hout AH, Wendt CC, Dunning AM, Pharoah PDP, Devilee P, Easton DF, James PA, Spurdle AB. Co-observation of germline pathogenic variants in different breast cancer predisposition genes: results from analysis of the BRIDGES sequencing dataset. *Am. J. Hum. Genet.*, 111(9): 2059-2069, 2024

**58-** Tsohandaridis I, Brisimis D, Tsifintaris M, Anastasiadou A, Lazos E, Ermogenous A, Christou S, Antonopoulou N, Panayiotidis MI, Koukourakis MI, Giatromanolaki A, Pappa A. Exploring the role and pathophysiological significance of aldehyde dehydrogenase 1B1 (ALDH1B1) in human lung adenocarcinoma. *Int. J. Mol. Sci.*, 25(19): 10301, 2024

**59-** Ververis A, Kyriakou S, Paraskeva C, Panayiotidis MI, Plioukas M, Christodoulou K. Chemical characterization and assessment of the neuroprotective potential of *Euphrasia officinalis*. *Int. J. Mol. Sci.*, 25(23): 12902, 2024

**60-** Anestopoulos I, Kyriakou S, Deligiorgi MV, Trafalis DT, Botaitis S, Giatromanolaki AN, Franco R, Koukourakis MI, Pappa A, Panayiotidis MI. Phytochemicals with epigenetic properties and their role in melanoma therapy. *Int. Rev. Cell Mol. Biol.*, 2025 (in press)

**61-** Theodoulou A, Speckmann T, Potamiti L, Baba O, Morita T, Drousiotou A, Panayiotidis MI, Schurmann A, Petrou PP. Stbd1 stimulates AMPK signalling and alleviates insulin resistance in an *in vivo* hepatocyte model. *FEBS J.*, 2025 (in press)

**62-** Anestopoulos I, Paraskevaidis I, Kyriakou S, Potamiti L, Trafalis DT, Botaitis S, Franco R, Pappa A, Panayiotidis MI. Isothiocyanates enhance the anti-melanoma effect of Zebularine through modulation of apoptosis and regulation of DNMTs' expression, chromatin configuration and histone posttranslational modifications associated with altered gene expression patterns. *Epigenomes*, 2025 (in press)

## PUBLICATIONS IN CONFERENCE ABSTRACTS

- 1- Hapeshi E, Kyriakou S, Panagiotidis MI, Primikyri A, Galatou E, Nicolaidou V, Zacharia L, Eleftheriou C, Tsinoglou S, Sarigiannis Y. First exploitation of the *Mesobuthus Cyprius* venom. *1<sup>st</sup> International Electronic Conference on Toxins, 2021*
- 2- Cherian Lukose Cecil, Mantso T, Panayiotidis M, Birkett M. Effect of noble metal (M=Ag, Au) concentration on mechanical and biomedical properties of Ti-M matrix thin films co-deposited by magnetron sputtering. *World Symposium on Mechanical-Materials Engineering and Science, 2021, Prague, CZECH REPUBLIC*
- 3- Zia Abdul Wasy, Cherian Lukose Cecil, Panayiotidis M, Birkett M. Role of silver quantity on tribological performance of silver embedded diamond-like carbon coatings. *EVC16-16<sup>th</sup> European Vacuum Conference, 2021, Marseille, FRANCE*
- 4- Cherian Lukose Cecil, Anastopoulos I, Panayiotidis M, Birkett M. Mechanical performance of biocompatible Ti-Au thin films grown on glass and Ti6Al4V substrates. *TACT 2021 International Thin Films Conference, 2021, Taipei, TAIWAN*
- 5- Yiangou K, Saloustros E, Mavroudis D, Georgoulis V, Kyriacou K, Panayiotidis MI, Loizidou MA, Hadjisavvas A, Michailidou K. Evaluation of polygenic risk score for the prediction of breast cancer risk in Cretan women. *9<sup>th</sup> International Multithematic Bio-Medical Congress, 2021, Nicosia, CYPRUS*
- 6- Nicolaou O, Kousios A, Sokratous K, Potamiti L, Koniali L, Neophytou G, Papacharalampous R, Ioannou S, Zanti M, Ioannou K, Hadjisavvas A, Panagiotidis M, Kyriacou K. Comparative proteomic analysis of kidney tissues in *Col4a3* knockout mice manifesting Alport syndrome: towards the discovery of novel therapies. *34<sup>th</sup> European Renal Cell Study Group, 2022, Lemessos, CYPRUS*
- 7- Anastopoulos I, Paraskevidis I, Tragkola V, Kyriakou S, Panayiotidis MI. Development, efficacy and safety of a novel therapeutic protocol against an experimental model of human malignant melanoma. *European Society for Alternatives on Animal Testing (EUSAAT), 2022, Linz, AUSTRIA*
- 8- Louka P, Potamiti L, Panayiotidis MI, Skouridis P. The role of the TOG-domain protein CEP104 in cilia and embryonic development. *EMBO Cilia 2022, 2022, Cologne, GERMANY*
- 9- Zanti M, Loizidou MA, O'Mahoney D, Kakouri E, Marcou Y, Hadjisavvas A, Panayiotidis MI, Michailidou K. Large-scale sequencing of 34 putative susceptibility genes in Cypriot female breast cancer cases. *10<sup>th</sup> International Multithematic Bio-Medical Congress, 2022, Nicosia, CYPRUS*
- 10- Demosthenous N, Panayiotidis MI, Kyriakou S. Chemical characterization and biological evaluation of *Nasturtium officinale* (watercress) in an experimental model of human malignant melanoma. *10<sup>th</sup> International Multithematic Bio-Medical Congress, 2022, Nicosia, CYPRUS*
- 11- Anastopoulos I, Paraskevidis I, Panayiotidis MI. A novel adjuvant treatment protocol combining Tazemetostat with various synthetic isothiocyanates enhances apoptotic induction in an *in vitro* model of human malignant melanoma. *10<sup>th</sup> International Multithematic Bio-Medical Congress, 2022, Nicosia, CYPRUS*
- 12- Tragkola V, Anastopoulos I, Kyriakou S, Panayiotidis MI. Watercress extract-contained major phytochemicals induce a cytotoxic response by regulating the expression of key apoptotic gene targets in an *in vitro* model of human malignant melanoma. *10<sup>th</sup> International Multithematic Bio-Medical Congress, 2022, Nicosia, CYPRUS*
- 13- Anastopoulos I, Paraskevidis I, Giova L, Tragkola V, Kyriakou S, Panayiotidis MI. Tazemetostat-induced reduction of EZH2 enhances cellular sensitivity to apoptosis in an *in vitro* model of human malignant melanoma. *International Meeting on "Epigenetics and Epigenomics in Health & Disease", 2022, Brussels, BELGIUM*
- 14- Angeli S, Kousiappa I, Georgiades S, Papacostas S, Koupparis A, Christou Y, Loucaides G, Bashiardes S, Hadjisavvas A, Panagiotidis M, Jovanovic A, Nicolaou N. Effect of probiotics on autonomic nervous system function of patients with mild Alzheimer's disease. *12<sup>th</sup> Probiotics, Prebiotics & New Foods "Neutraceuticals, Botanicals & Phytochemicals for Nutrition & Human, Animal & Microbiota Health"; 3<sup>rd</sup> Science & Business Symposium, 2023, Rome, ITALY*



**15-** Wilcox N, Dumont M, González-Neira A, Carvalho S, Beauparlant CJ, Crotti M, Luccarini C, Soucy P, Dubois S, Nuñez-Torres R, Pita G, Gardner E, Dennis J, Alonso MR, Álvarez N, Baynes C, Collin-Deschesnes AC, Desjardins S, Becher H, Behrens S, Bolla MK, Castelao JE, Chang-Claude J, Cornelissen S, Dörk JT, Engel C, Gago-Dominguez M, Guénel P, Hadjisavvas A, Hahnen E, Hartman M, Herráez B, SGBCC Investigators, Jung A, Keeman R, Kiechle M, Li J, Loizidou MA, Lush M, Michailidou K, Panayiotidis MI, Sim X, Teo SH, Tyrer JP, van der Kolk LE, Wahlström C, Wang Q, Perry J, Benitez J, Schmidt MK, Schmutzler RK, Pharoah PDP, Droit A, Dunning AM, Kvist A, Devilee P, Easton DF, Simard J. Exome sequencing identifies novel susceptibility genes and defines the contribution of coding variants to breast cancer risk. *BRCA 2023: Moving into the Mainstream, 2023, Montreal, CANADA*

**16-** Zanti M, Loizidou MA, O'Mahoney D, Kakouri E, Marcou Y, Panayiotidis MI, Hadjisavvas A, Michailidou K. Whole-exome sequencing of 736 Cypriot female breast cancer cases and controls. *9<sup>th</sup> International Conference of the Cyprus Society of Human Genetics, 2023, Nicosia, CYPRUS*

**17-** Anastopoulos I, Paraskevaidis I, Kyriakos S, Giova L, Pappa A, Franco R, Panayiotidis MI. Drugging the epigenome of human malignant melanoma enhances therapeutic effectiveness of clinical epigenetic drugs: The case of Tazemetostat. *Society of Toxicology 62<sup>nd</sup> Annual Meeting and ToxExpo, 2023, Tennessee, USA*

**18-** Cherian Lukose Cecil, Anastopoulos I, Panagiotidis I-S, Panayiotidis MI, Birkett M. Biocompatibility profiling of new super hard Ti<sub>3</sub>Au thin film coatings doped with Ag/Cu. *BioFutures Symposium, 2023, Newcastle Upon Tyne, UK*

**19-** Kyriakou S, Potamiti L, Demosthenous N, Panayiotidis MI. Naturally-derived phenethyl isothiocyanate induces perturbations in cellular oxidative status and promotes Ca<sup>2+</sup> dependent activation of intrinsic apoptosis via subcellular ultrastructural alterations in an in vitro model of human malignant melanoma. *8<sup>th</sup> International Conference on Oncology and Anticancer Research (ICOAR); 11th International Conference on Recent Advances in Health and Medical Sciences (RAHMS); 29<sup>th</sup> International Conference on Chelation (ICOC), 2023, Paphos, CYPRUS*

**20-** Tragkola V, Anastopoulos I, Kyriakou S, Panayiotidis MI. Naturally-derived watercress modulates the expression of key apoptotic genes in a model of human malignant melanoma. Implications for the development of novel experimental cancer therapeutic strategies. *8<sup>th</sup> International Conference on Oncology and Anticancer Research (ICOAR); 11th International Conference on Recent Advances in Health and Medical Sciences (RAHMS); 29<sup>th</sup> International Conference on Chelation (ICOC), 2023, Paphos, CYPRUS*

**21-** Kyriakou S, Anastopoulos I, Potamiti L, Demosthenous N, Amery T, Stewart K, Winyard PG, Franco R, Pappa A, Panayiotidis MI. Naturally-derived isothiocyanate compounds differentially modulate cytotoxicity as a means of their anticancer potency in malignant melanoma. *Society of Toxicology 63<sup>rd</sup> Annual Meeting and ToxExpo, 2024, Utah, USA*

**22-** Potamiti L, Yiallourous PK, Kouis P, Anagnostopoulou P, Kyriacou K, Panayiotidis MI. Performance and detection rate of transmission electron microscopy for primary ciliary dyskinesia diagnosis in Cyprus. *International European Reference Network (ERN) – Primary Ciliary Dyskinesia (PCD) Meeting, 2024, Nicosia, CYPRUS*

## FUNDING

### Role as a Principal Investigator

#### Completed

- Horizon-Europe Research and Innovation Action (RIA) grant: “*Adaptation to climate change in the rhizosphere across the millennia (TOLERATE)*”, Funder: European Research Executive Agency; Budget: €3,909,870; Duration: 2023-2027
- Marie Skłodowska-Curie Actions “Staff Exchanges” grant: “*Multi-Actor Research and Innovation Approaches for Functional Food (RIA4FOOD)*”, Funder: European Research Executive Agency; Budget: €1,628,400; Duration: 2023-2027





- RESTART 2016-2020 “Research Infrastructures Programme - Strategic Infrastructures” grant: “*Cyprus Space Research and Innovation Centre (An ICT / Space Laboratory)*”, Funder: Cypriot Research and Innovation Foundation; Budget: €2,500,000; Duration: 2023-2026
- Internal Grant: “*Epigenetic Cancer Therapeutics in Malignant Melanoma*”, Funder: TELETHON - CYPRUS; Budget: €133,143; Duration: 2020-2024
- Pump Priming Collaboration between UK and EU Partners grant: “*Advanced Bioactive Diamond-like Carbon-based Coatings for Next Generation Orthopaedic Implants*”, Funder: The British Academy; Budget: £9,892; Duration: 2022
- Horizon-2020 Research and Innovation Action (RIA) grant: “*Novel, sustainable marine bio-surfactants/ bio-emulsifiers for commercial exploitation (MARISURF)*”, Funder: European Research Executive Agency; Budget: €4,749,649; Duration: 2015-2021

## **Role as a Co-Principal Investigator**

### **Active**

- Research Program grant: 1<sup>st</sup> Call for HFRI Research Projects to Support Faculty Members and Researchers and the Procurement of High-Cost Research Equipment: “*BioActiveScreen Research Infrastructure in Northern Greece: Identification of endemic aromatic plant-derived bioactive compounds of high-added value (BioActiveScreen)*”, Funder: Greek Foundation for Research and Innovation (HFRI); Budget: €1,500,000; Duration: 2022-2025

### **Completed**

- Research Grant 2022: “*Identifying unique characteristics of extracellular vesicles circulating in Myotonic Dystrophy type 1 patients and their use as blood-based biomarkers*”, Funder: French AFM-TELETHON; Budget: €150,600; Duration: 2022-2024
- 2021 RFA grant: Target Advancement Program: “*Increased levodopa treatment efficacy by targeting Enterococcus faecalis*”, Funder: The Michael J Fox Foundation; Budget: \$196,489; Duration: 2021-2023
- Collaboration Grant: “*Untargeted proteomic analysis and profiling in Cypriot Huntington’s disease patients*”, Funder: European Huntington’s Disease Network; Budget: €45,868; Duration: 2021-2023
- Marie Skłodowska-Curie Individual Fellowships: “*High-performance biocompatible Ag-DCL coatings-Precise and localized silver doping through novel helium pulse injections*”, Funder: European Research Executive Agency; Budget: €224,934; Duration: 2021-2023
- Research Project Grant: “*Super hard biocompatible coatings of beta Ti3Au*”, Funder: Leverhulme Trust; Budget: £224,630; Duration: 2018-2022

## **Role as an External Collaborator**

### **Completed**

- Alzheimer's Association Research Grant - New to the Field (AARG-NTF): “*Effect of probiotics on cognitive functioning of patients with early Alzheimer’s disease*”, Funder: Alzheimer’s Association, USA; Budget: \$119,733; Duration: 2022-2024

## **INVITED PRESENTATIONS**

- Graduate Program in “*Translational Research in Biomedicine: Molecular Diagnostics, Biomarkers and Targeted Therapies*”; Department of Molecular Biology & Genetics, Democritus University of Thrace, Alexandroupolis, Greece (2019-2025)
- 8<sup>th</sup> International Conference on Oncology and Anticancer Research (ICOAR); 11<sup>th</sup> International Conference on Recent Advances in Health and Medical Sciences (RAHMS); 29<sup>th</sup> International Conference on Chelation (ICOC), Paphos, Cyprus (2023)



- Workshop on “Advanced technologies for bioactivity screening of compounds in natural products”; Department of Molecular Biology & Genetics, Democritus University of Thrace, Alexandroupolis, Greece (2023)
- School of Veterinary Medicine and Biomedical Sciences Seminar Series, School of Veterinary Medicine & Biomedical Sciences, University of Nebraska-Lincoln, USA (2023)
- MediEuro Network “Biobanking and Biomedical Research”; University of Cyprus, Cyprus (2022)

## CONFERENCE COMMITTEES & CHAIR SESSIONS

- *Secretary*, International Organizing and Scientific Committee (IOSC), 8<sup>th</sup> International Conference on Oncology and Anticancer Research (ICOAR); 11<sup>th</sup> International Conference on Recent Advances in Health and Medical Sciences (RAHMS); 29<sup>th</sup> International Conference on Chelation (ICOC), 2023, Paphos, Cyprus
- *Chair*, Sessions on “Natural and Food Products in Health and Disease”, “Advances in Medical Sciences”, “Advances in Molecular Environmental and Medical Sciences”, 8<sup>th</sup> International Conference on Oncology and Anticancer Research (ICOAR); 11<sup>th</sup> International Conference on Recent Advances in Health and Medical Sciences (RAHMS); 29<sup>th</sup> International Conference on Chelation (ICOC), 2023, Paphos, Cyprus

## TEACHING EXPERIENCE (LAST 5 YEARS)

### 1- Co-ordinator and Co-Instructor for MM102: Molecular Basis of Complex Diseases; CING Postgraduate School, Cyprus Institute of Neurology & Genetics, Cyprus (Fall Semesters 2020-2024);

*Course description:* This comprehensive lecture course discusses current aspects in the field of complex disorders with emphasis on molecular mechanisms involved in the pathogenesis and therapeutic management of various cancer types as well as other cardiovascular, skin, gastrointestinal, respiratory and prostate disorders. Furthermore, the use of new technologies (high throughput genotyping, functional genomics, proteomics, model organisms and bioinformatics) and exposure to cutting-edge knowledge (pharmacogenomics, personalized medicine, molecular diagnostics, biomarker discovery) together with real-life applications in contemporary medicine are covered, at lectures, when applicable. Finally, relevant clinical (demographics, risk factors, early diagnosis, prevention, therapy, use of biomarkers) and histological aspects regarding disease severity are also examined; *Topics taught:* pathogenesis of human disease, molecular pathology of skin, gastrointestinal tract, lung and prostate diseases, molecular basis of cancer, pharmacogenomics and personalized medicine, tutorials, assessments (student paper presentations), laboratory demonstrations (electron microscopy and molecular diagnostics)

## CLINICAL DIAGNOSTIC EXPERIENCE

1- **Department of Cancer Genetics, Therapeutics & Ultrastructural Pathology, The Cyprus Institute of Neurology & Genetics, Cyprus (2019-2024).** I have directed the department’s services and other related activities in ultrastructural pathology and cancer genetics / pharmacogenetics. Specifically, the department offers 1) ultrastructural diagnostic testing for various diseases (neuromuscular, kidney and ciliary) by operating the only Transmission Electron Microscope available in Cyprus; and 2) molecular testing in diagnosing genetic cancer predisposition (cancer genetics) and somatic mutations as targets for personalized therapy (pharmacogenetics). A typical workload includes around 1500 clinical samples / per year in addition to contributing expertise and technical “know-how” in various research projects by means of research planning and design as well as data curation and analysis. Examples include: i) the Breast Cancer Association Consortium (<https://bcac.ccge.medschl.cam.ac.uk>) which represents a consortium of investigators interested in the inherited risk of breast cancer by conducting studies with the aim of identifying genes related to the risk of breast cancer; and ii) the Consortium of Investigators of Modifiers of BRCA1/2 (<https://cimba.ccge.medschl.cam.ac.uk>) which represents a consortium of investigators working on genetic modifiers of cancer risk in BRCA1 and BRCA2 mutation carriers with the aim to

provide sufficient sample sizes, to large scale studies, in order to evaluate reliably the effects of genetic modifiers.

## MANAGEMENT EXPERIENCE

**1- Department Head of Cancer Genetics, Therapeutics & Ultrastructural Pathology, The Cyprus Institute of Neurology & Genetics, Cyprus (2019-2024).** I have led all activities relevant to i) staff evaluations; ii) academic development of permanent and temporary staff; iii) management of budget, financial planning and analysis; iv) advocacy of research, teaching and administration tasks amongst staff; v) curriculum development of the postgraduate degree program in Molecular Medicine as well as the content of the “Molecular Basis of Complex diseases” course taught primarily by department staff; vi) recruitment of new staff and promotion/regrading of existing staff; vii) leadership in the planning and implementation of the institutional and departmental strategy plan; viii) public engagement and outreach activities and ix) departmental representation to the Institute’s Scientific Committee, Academic Staff Evaluation & Regrading Committee, Academic Committee, Admissions Committee and Postgraduate School Council Committee.

**2- Director of the -omics Core Facility, The Cyprus Institute of Neurology & Genetics, Cyprus (2019-2024).** I have directed all activities of the Institute’s core facility in Metabolomics/ Lipidomics which contributes expertise and technical competence into various research and clinical projects in need to utilize analytical instruments such as the Agilent’s REVIDENT Q-TOF LC/MS system (for routine screening, high resolution, accurate-mass quantitation, identification of unknowns, and high-throughput testing for small molecule applications in metabolomics / lipidomics analyses) as well as the Waters’ XEVO TQD UPLC system (with a triple quadrupole MS core for routinely quantification experiments of known analytes).

**3- Director of the Biobank Core Facility, The Cyprus Institute of Neurology & Genetics, Nicosia, Cyprus (2019-2024).** I have directed all activities of the Institute’s biobank core facility by providing service to various research and clinical projects in the context of collecting, processing, storing and archiving of biological samples from patients with various diseases. The Biobank facility meets all national and European standards and it is a full member of the European Biobanking & Biomolecular Resources Research Infrastructure (BBMRI-ERIC) (<https://www.bbmri-eric.eu>).

## EDITORIAL EXPERIENCE

### GUEST EDITOR

- *Antioxidants*

### ASSOCIATE EDITOR

- *Pharmacology & Therapeutics, Frontiers in Nutrition, Frontiers in Pharmacology*

### ACADEMIC EDITOR

- *Medicine*

### EDITORIAL BOARD MEMBER

- *Scientific Reports, Molecular Medicine Reports, Antioxidants, Toxicology Mechanisms & Methods, International Journal of Experimental Pathology*

### AD HOC JOURNAL REVIEWER

- *Toxicology Journals: Toxicological Sciences, Toxicological & Environmental Chemistry, Human & Experimental Toxicology, Toxicology Letters, Mutation Research-Genetic Toxicology &*



Environmental Mutagenesis, Experimental & Toxicologic Pathology, Archives of Toxicology, Ecotoxicology & Environmental Safety, Toxicology Mechanisms & Methods, Toxicology in Vitro, Particle & Fibre Toxicology, Food & Chemical Toxicology, Journal of Toxicology & Health, Ecotoxicology, BMC Pharmacology & Toxicology, Journal of Biochemical & Molecular Toxicology

- **Nutrition & Food Journals:** Annals of Nutrition & Metabolism, African Journal of Plant Science, International Journal for Vitamin & Nutrition Research, Journal of Nutritional Health & Food Science, Journal of Food & Nutrition Research, Journal of Nutritional Health & Food Engineering, International Food Research Journal, Nutrients, Phytotherapy Research, Antioxidants
- **Cancer Journals:** Cancer Letters, Anti-Cancer Drugs, Journal of Cancer Science & Therapy, Oncology Reports, Oncology Letters
- **Chemistry Journals:** Clinica Chimica Acta, Chemico-Biological Interactions, Bioorganic & Medicinal Chemistry, Biochemical Biophysical Acta, ACS Medicinal Chemistry Letters, Redox Reports, Molecules, Dose-Response
- **Pharmacology Journals:** Scientia Pharmaceutica, Biochemical Pharmacology
- **Epigenetics Journals:** Clinical Epigenetics
- **Biology Journals:** Immunobiology, International Journal of Biological Sciences, International Journal for Biofactors, Biology, Biomed Research International, Cellular & Molecular Life Sciences, Scientific Reports, International Journal of Molecular Sciences, International Journal of Experimental Pathology, Anaerobe, Beneficial Microbes, Radiation Research, Mutagenesis, Xenobiotica
- **Bioengineering Journals:** Materials Science & Engineering C: Materials for Biological Applications
- **Multidisciplinary Journals:** iScience

## **PUBLIC ENGAGEMENT & OUTREACH EXPERIENCE**

- European Researchers' Night 2024 under the theme of "extraction and isolation of anti-cancer compounds from aromatic plants" for educating the public on the role of plant-based compounds in cancer drug development, Nicosia, Cyprus (2024)
- Fund-raising and other promotional live radio broad-casting events organized by the TELETHON - Cyprus charity for supporting research programmes at the Cyprus Institute of Neurology & Genetics in assisting patients with muscular dystrophy, Nicosia, Cyprus (2023-2024)
- Panel discussion on the challenges oncology faces as part of giving undergraduate as well as graduate students the opportunity to finding innovative solutions to healthcare challenges while experiencing building their own company, The Innovate in Healthcare Entrepreneurial Bootcamp, Junior Achievement Cyprus, Nicosia, Cyprus (2023)
- TV and live radio broad-casting events organized by the Cyprus Institute of Neurology & Genetics for promoting its research and clinical diagnostic services, in cancer genetics and therapeutics, for the benefit of cancer patients, Nicosia, Cyprus (2022-2024)
- Presentation events, at the Cyprus Institute of Neurology & Genetics, for senior high school and undergraduate university students on a career in biomedical research, Nicosia, Cyprus (2021-2024)

## **PROFESSIONAL AFFILIATIONS**

### **PROFESSIONAL ASSOCIATIONS**

- *Member* of the Society of Toxicology
- *Member* of the Cyprus Society for Human Genetics
- *Member* of the European Society of Toxicology in Vitro
- *Member* of the Hellenic Association of Medical Geneticists
- *Member* of the Education Quality Accreditation Commission



## **INTERNATIONAL NETWORKS**

- *Management Committee Member* of the European Cooperation in Science & Technology “COST” Action on Cancer-Understanding Prevention in Intellectual Disabilities (2022-2024)
- *Management Committee Member* of the European Cooperation in Science & Technology “COST” Action on European Network for Skin Engineering and Modelling (2022-2024)
- *Management Committee Member* of the European Cooperation in Science & Technology “COST” Network on Rethinking Packaging for Circular and Sustainable Food Supply Chains of the Future (2021-2024)
- *Member* of the International Network for Responsible Biosciences (2022-2024)
- *Member* of the European Reference Network on Respiratory Diseases (2021-2024)
- *Member* of the European Huntington’s Disease Network (2020-2024)
- *Member* of the European Paediatric Translational Research Infrastructure (2020-2024)
- *Member* of the European Reference Network on Rare Genetic Tumor Risks Syndromes (2020-2024)

## **INTERNATIONAL CONSORTIA**

- *Member* of the Breast Cancer Association Consortium (2022-2024)
- *Member* of the Consortium of Investigators of Modifiers of BRCA1/2 (2022-2024)
- *Member* of the Task Force on Shared Molecular Aetiologies Underlying Multiple Rare Diseases of the International Rare Diseases Research Consortium (2021-2023)